DiMartino-Nardi J, Wesoly S, Schwartz L, Saenger P
Department of Pediatrics, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY 10467.
Metabolism. 1993 Jun;42(6):730-4. doi: 10.1016/0026-0495(93)90240-o.
In adults patients, administration of human growth hormone and growth hormone synthesized by recombinant DNA technology (rGH) results in sodium and fluid retention and weight gain. This study was performed to determine whether rGH administration in children with idiopathic short stature (ISS) caused any clinical evidence of sodium retention. The parameters assessed included blood pressure, height, weight, plasma renin activity (PRA), aldosterone, and atrial natriuretic peptide (ANP). These were measured in nine treated children after 0, 3, 6, 9, and 12 months of growth hormone therapy; seven untreated children served as controls. After 12 months, the treated children had no significant increases in measurements of blood pressure, PRA, aldosterone, and ANP. Although treated children gained more weight than control patients, they also grew faster. Therefore, there was no significant difference in weight for height percentile for treated children when compared with normal controls. After 1 year of therapy, the administration of rGH to children with ISS does not result in any clinically significant evidence of sodium retention.
在成年患者中，使用人类生长激素以及通过重组DNA技术合成的生长激素（rGH）会导致钠和液体潴留以及体重增加。本研究旨在确定对特发性身材矮小（ISS）儿童使用rGH是否会引起任何钠潴留的临床证据。评估的参数包括血压、身高、体重、血浆肾素活性（PRA）、醛固酮和心钠素（ANP）。在生长激素治疗0、3、6、9和12个月后，对9名接受治疗的儿童进行了这些指标的测量；7名未接受治疗的儿童作为对照。12个月后，接受治疗的儿童在血压、PRA、醛固酮和ANP的测量值上没有显著增加。虽然接受治疗的儿童比对照患者体重增加更多，但他们生长得也更快。因此，与正常对照相比，接受治疗的儿童身高体重百分位数没有显著差异。经过1年的治疗，对ISS儿童使用rGH不会导致任何临床上显著的钠潴留证据。
